<div id="readability-page-1"><p>Dexcom (<span>DXCM</span>) has disclosed a new risk, in the Share Price &amp; Shareholder Rights category.</p><h3>Valentine's Day Sale - 70% Off</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential</li></ul> <p>Dexcom’s 2025 Share Repurchase Program, authorized for up to $750 million through June 30, 2026, may not be fully executed and offers no assurance of enhancing long‑term shareholder value. External factors such as market volatility, competing capital allocation needs, and discretionary timing could limit repurchases or result in buybacks at prices that fail to improve EPS or sustain the stock price.</p> <p>Overall, Wall Street has a Strong Buy <span>consensus rating</span> on DXCM stock based on 17 Buys, 1 Sell and 3 Holds.</p> <p>To learn more about Dexcom’s risk factors, <span>click here</span>.</p></div>

DXCM

SBIO

<p>Dexcom has announced a $750 million share repurchase program for 2025, but its execution may be uncertain due to market volatility and competing capital needs. There is no guarantee that the buyback will enhance long-term shareholder value. Despite this, Wall Street maintains a Strong Buy consensus on DXCM stock, with 17 Buys, 1 Sell, and 3 Holds.</p>

Tip Ranks

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

DexCom

ALPS Medical Breakthrough

iShares US Medical Devices

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

VanEck Biotech ETF

Dexcom’s $750 Million 2025 Buyback Plan Faces Uncertain Execution and Limited Assurance of Shareholder Value